IQVIA

Certara

Follow

Certara is a growing company that provides an exciting place to work. Our purpose is to help accelerate the development of meaningful medicines that make an impact on our society and the people who need them most. Innovation and creativity are highly valued, and everyone is given the opportunity for training and continuous development. Our portfolio spans the discovery, preclinical, clinical and post-marketing phases of drug development, working with 1,600 organizations across 60 countries and numerous regulatory agencies.

Dun & Bradstreet

Follow

Dun & Bradstreet unlocks the power of data through analytics, creating a better tomorrow. We are guided by timeless values that make us the established leader in actionable data and insights.  Our information is valuable at all phases of the business lifecycle and whatever the economic environment.

Gilead Sciences

Follow

Gilead Sciences is a global biopharmaceutical company with over 17,000 employees focused on discovering, developing, and delivering innovative medicines for people with serious diseases. For nearly four decades, Gilead has contributed to advances in HIV treatment and prevention and continues to expand research across oncology, liver disease, and inflammatory conditions. Our work spans the full lifecycle of medicine development, including scientific research, clinical trials, manufacturing, and global commercialization. Teams across research, clinical development, manufacturing, and corporate functions collaborate to translate scientific discovery into therapies that reach patients worldwide. Gilead operates in more than 35 countries and partners with healthcare providers, research institutions, and global organizations to improve access to medicines and support public health initiatives. Through Kite Pharma, Gilead also advances cell therapy research, including CAR-T therapies designed to treat certain cancers. Kite’s work represents a key component of Gilead’s oncology strategy and investment in next-generation therapeutic approaches.